Support for LAist comes from
Local and national news, NPR, things to do, food recommendations and guides to Los Angeles, Orange County and the Inland Empire
Stay Connected
Listen

Share This

News

FDA Authorizes Johnson & Johnson's One-Shot COVID-19 Vaccine

A South African healthcare worker holds a dose of the Johnson & Johnson vaccine against the COVID-19 coronavirus. The U.S. authorized its use Saturday.(Phill Magakoe / AFPGetty Images)
()

Congress has cut federal funding for public media — a $3.4 million loss for LAist. We count on readers like you to protect our nonprofit newsroom. Become a monthly member and sustain local journalism.

By Scott Hensley| NPR

Our news is free on LAist. To make sure you get our coverage: Sign up for our daily newsletters. To support our non-profit public service journalism: Donate Now.

The Food and Drug Administration authorized Johnson & Johnson's vaccine for emergency use Saturday, a day after a panel of advisers to the agency voted unanimously (22-0) in its favor.

"The authorization of this vaccine expands the availability of vaccines, the best medical prevention method for COVID-19, to help us in the fight against this pandemic, which has claimed over half a million lives in the United States," said a statement by Acting FDA Commissioner Janet Woodcock.

Support for LAist comes from

The Single Shot COVID-19 Vaccine Is Coming Soon. How Many Doses Will LA County Get?


The Johnson & Johnson vaccine was tested in an international study of about 40,000 people, half of whom got the vaccine and half of whom got a placebo. The study found the company's vaccine to be 66% effective overall in preventing moderate to severe COVID-19 disease. For disease judged severe or critical, the effectiveness was 85%. The study was conducted in the U.S., South America and South Africa.

The main study included in the company's application found that 28 days or more after immunization, the Johnson & Johnson vaccine prevented hospitalizations and deaths related to COVID-19.

The overall efficacy figures are lower than Pfizer's 95% in preventing COVID-19 disease and 94% for Moderna. But direct comparisons are challenging because of differences in the clinical trials and emergence of new strains of the coronavirus.

The Johnson & Johnson vaccine "is very effective ... at preventing severe disease after a single dose and it induces the kind of response, so-called cellular immune response, that looks like it's going to have fairly long-lived memory, which is all good," Dr. Paul Offit, a member of the FDA's advisory panel, told NPR's Scott Simon on Weekend Edition Saturday. "This certainly provides protection against what you care about, which is hospitalization, ICU admission and death. It's virtually 100% effective at doing that." Offit is also director of the Vaccine Education Center at the Children's Hospital of Philadelphia.

Support for LAist comes from

As the pandemic has drawn on, the coronavirus has mutated. Variants first seen in South Africa and Brazil, where the Johnson & Johnson vaccine was tested, developed mutations that help them evade the immune response prompted by previous infections with the original form of the virus and vaccines designed against it. Some of the variants, including one first identified in the U.K, are more contagious.

In the South African portion of the Johnson & Johnson study, the company's vaccine was 64% effective in preventing moderate to severe disease. In the Latin American region, the vaccine was 61% effective.

As Editor-in-Chief of our newsroom, I’m extremely proud of the work our top-notch journalists are doing here at LAist. We’re doing more hard-hitting watchdog journalism than ever before — powerful reporting on the economy, elections, climate and the homelessness crisis that is making a difference in your lives. At the same time, it’s never been more difficult to maintain a paywall-free, independent news source that informs, inspires, and engages everyone.

Simply put, we cannot do this essential work without your help. Federal funding for public media has been clawed back by Congress and that means LAist has lost $3.4 million in federal funding over the next two years. So we’re asking for your help. LAist has been there for you and we’re asking you to be here for us.

We rely on donations from readers like you to stay independent, which keeps our nonprofit newsroom strong and accountable to you.

No matter where you stand on the political spectrum, press freedom is at the core of keeping our nation free and fair. And as the landscape of free press changes, LAist will remain a voice you know and trust, but the amount of reader support we receive will help determine how strong of a newsroom we are going forward to cover the important news from our community.

Please take action today to support your trusted source for local news with a donation that makes sense for your budget.

Thank you for your generous support and believing in independent news.

Chip in now to fund your local journalism
A row of graphics payment types: Visa, MasterCard, Apple Pay and PayPal, and  below a lock with Secure Payment text to the right
(
LAist
)

Trending on LAist